NCT04813653View on ClinicalTrials.gov

Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells

PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

April 18, 2021

Primary Completion Date

March 5, 2025

Study Completion Date

March 5, 2025

Conditions
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Interventions
DRUG

cyclosporine in combination with carfilzomib and dexamethasone

patients will be treated with cyclosporine with dose titration based on repeated determinations of whole blood concentrations to achieve a target trough concentration of 250 ng/mL, in combination with carfilzomib plus dexamethasone.

Trial Locations (1)

Unknown

Tel Aviv Sourasky Medical Center, Tel Aviv

All Listed Sponsors
collaborator

Weizmann Institute of Science

OTHER

lead

Tel-Aviv Sourasky Medical Center

OTHER_GOV